Citius Oncology, Inc. CTOR Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate at other companies

Norwood FinancialNWFL

4.5%0.0pp

CHE

ChemedCHE

0.5%+0.2pp

BeldenBDC

0.2%-0.1pp

RBC BearingsRBC

0%—

Ispire Technology Inc.ISPR

0%—

Cineverse Corp.CNVS

0%—

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Operating cash flow-$3.8M-179%

Market cap$60.45M-74.7%

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.

The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Citius Oncology, Inc.'s share based compensation arrangement by share based payment award fair value assumptions expected dividend rate?: Citius Oncology, Inc. (CTOR) reported share based compensation arrangement by share based payment award fair value assumptions expected dividend rate of 0% in Q3 2025.
What does share based compensation arrangement by share based payment award fair value assumptions expected dividend rate mean?: The expected dividend yield assumption utilized in the valuation of share-based payment awards. It reflects the anticipated dividend payments over the life of the option, which inversely affects the fair value of the granted equity instruments.